AstraZeneca PLC on Thursday said Calquence, when used in combination with obinutuzumab, showed a longer-term survival rate in people with a form of leukaemia.
People with 1st-line chronic lymphocytic leukaemia treated with the two medications had a higher survival rate at five years compared to people who were treated with chlorambucil and obinutuzumab.
The Cambridge-based pharmaceutical company said it will provide a pipeline and portfolio across malignant and rare haematological diseases at the European Hematology Association annual meeting, which takes place from Thursday to Sunday.
‘A total of five approved and potential new medicines from AstraZeneca will be featured across 16 abstracts, including one oral presentation,’ the company said.
AstraZeneca shares were 0.8% lower at 10,232.00 pence each in London on Thursday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
